Related Experiment Video
Updated: Oct 21, 2025
Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
Published on: May 9, 2022
C3-targeted therapy in periodontal disease: moving closer to the clinic
George Hajishengallis1, Hatice Hasturk2, John D Lambris3
1University of Pennsylvania, Penn Dental Medicine, Department of Basic and Translational Sciences, Philadelphia, PA, USA.
Insights
Targeting complement component 3 (C3) effectively reduced gum inflammation in a clinical study for periodontal disease. This C3 inhibition therapy shows promise for treating periodontitis.
Area of Science:
- Immunology
- Periodontal disease research
- Host-modulation therapy
Background:
- The complement system is crucial for immune function but can cause harm when dysregulated.
- Overactivation of complement, particularly C3, is implicated in inflammatory conditions like periodontal disease.
- Previous studies indicated complement hyperactivation in periodontitis.
Purpose of the Study:
- To evaluate the therapeutic potential of targeting complement component 3 (C3) for periodontal disease.
- To assess the efficacy of C3 inhibition as a host-modulation therapy in periodontitis.
Main Methods:
- Preclinical studies in nonhuman primates (NHPs) investigated C3-targeted drug efficacy.
- A Phase IIa clinical trial was conducted to test C3 inhibition in patients with periodontal disease.
Main Results:
- C3 inhibition demonstrated therapeutic benefits in NHPs with periodontitis.
- The C3-targeted drug candidate showed favorable safety and pharmacokinetic profiles.
- Clinical administration of C3 inhibition successfully resolved gingival inflammation in patients.
Conclusions:
- Targeting complement component 3 (C3) is a viable therapeutic strategy for periodontal disease.
- C3 inhibition represents a novel host-modulation therapy with potential for further clinical development.
- Further Phase III clinical trials are warranted to confirm the efficacy of C3-targeted interventions for periodontitis.
Abstract:
Complement plays a key role in immunosurveillance and homeostasis. When dysregulated or overactivated, complement can become a pathological effector, as seen in several inflammatory disorders, including periodontal disease. Recently, clinical correlative studies and preclinical mechanistic investigations have collectively demonstrated that complement is hyperactivated during periodontitis and that targeting its central component (C3) provides therapeutic benefit in nonhuman primates (NHPs). The preclinical efficacy of a C3-targeted drug candidate combined with excellent safety and pharmacokinetic profiles supported its use in a recent Phase IIa clinical study in which C3 inhibition resolved gingival inflammation in patients with periodontal disease. We posit that C3-targeted intervention might represent a novel and transformative host-modulation therapy meriting further investigation in Phase III clinical trials for the treatment of periodontitis.
